Related Experiment Videos
[Present and future developments of antithrombotic agents]
1Institut de cardiologie, Groupe hospitalier La Pitié-Salpêtrière, Paris.
Insights
New antithrombotic strategies balance efficacy and bleeding risk in cardiology. Higher clopidogrel doses and novel agents like prasugrel show promise, alongside improved thrombin inhibitors for interventional procedures.
Area of Science:
- Cardiology
- Pharmacology
Context:
- Interventional cardiology necessitates balancing antithrombotic efficacy with bleeding risk.
- Development of novel antithrombotic agents and strategies is ongoing.
- Existing agents like clopidogrel are being evaluated at higher dosages (600 mg, 900 mg) and long-term administration.
Purpose:
- To review advancements in antithrombotic therapies for interventional cardiology.
- To evaluate new antithrombotic agents and their clinical potential.
- To discuss evolving administration strategies for improved patient outcomes.
Summary:
- Higher doses of clopidogrel (600 mg, 900 mg) demonstrate improved biological effects warranting further clinical trials.
- Newer thienopyridines, such as prasugrel, exhibit potent effects and have undergone large-scale clinical assessment.
- Antiplatelet GPIIb/IIIa inhibitors are being reconsidered in new administration strategies.
- Direct and indirect thrombin inhibitors are being developed to replace unfractionated heparin, offering more predictable activity.
- Low molecular weight heparins provide easier administration compared to unfractionated heparin.
- Synthetic factor Xa inhibitors are in early developmental stages.
- Bivalirudine, a direct thrombin antagonist, offers an improved benefit/risk profile for catheter laboratory procedures.
Impact:
- Novel antithrombotic agents and strategies may optimize the balance between preventing thrombosis and minimizing bleeding complications.
- Bivalirudine presents a new, favorable option for anticoagulation during periprocedural care.
- Ongoing research and clinical trials are crucial for validating the efficacy and safety of these emerging antithrombotic therapies.
Abstract:
The search for the optimal antithrombotic efficacy to bleeding risk ratio in interventional cardiology has promoted the development of new antithrombotics and to the elaboration of new association strategies. The relatively modest and inconstant antiaggregant effect of 300 mg of clopidogrel has led to the use of higher dosages of 600 mg or 900 mg. The improved biological effects justify clinical evaluation on a larger scale. While waiting for the results of the CHARISMA trial, several studies seem to demonstrate the benefits of long-term administration. New thienopyridines, the leader of which is prasugrel, have powerful biological effects and have already been assessed in larger clinical trials. The anti GPIIb/IIIa molecules, the indications of which have been recently redefined, feature in new administration strategies under evaluation. The use of direct or indirect thrombin antagonists during invasive procedures remains necessary and several molecules are candidates for replacing unfractionated heparin, with a more predictable activity. Low molecule weight heparins have been shown to be easier to use compared with unfractionated heparin. Synthetic factor Xa inhibitors are at an early stage of development. Of the direct thrombin antagonists, bivalirudine provides an improved benefit/risk ratio and is a new option in the catheter laboratory.
Related Concept Videos
01:18Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:29Venous Thrombosis III: Interprofessional Care
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
01:26Atherosclerosis III: Management
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...